NMDA-targeted medicine to treat bipolar I depression
Treatments studied
Part of Mental health clinical trials.
This Phase 2 study tests a medication that works on NMDA receptors to improve depression symptoms in people with bipolar I disorder. It may help if you’re currently in a bipolar depression episode and other mood treatments haven’t fully controlled it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have bipolar I disorder and your current episode is depression
- You’ve already tried stable treatment for at least 4 weeks with quetiapine and/or lurasidone and/or a mood stabilizer
- Your baseline depression score is high enough, and your current mania symptoms are low (specific rating scales used by the study)
- You do not have substance abuse/dependence in the last 6 months
- You are able to take part safely, including avoiding pregnancy or breastfeeding and being able to follow study instructions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called LB-102 for people with bipolar I disorder who are currently experiencing a major depressive episode without psychosis. It aims to see if the drug is safe and effective for treating depression symptoms.
This trial tests an experimental drug called NBI-1117568 for people with bipolar I disorder who are currently having a manic or mixed episode. The goal is to see if the drug helps calm mania symptoms and is safe.
This trial tests whether the study drug azetukalner can help reduce depression symptoms in people with bipolar I or II disorder who are currently having a depressive episode. You would be randomly assigned to receive either the drug or a placebo (inactive pill) to see which works better.
This trial studies an NMDA-based treatment for people with major depressive disorder who did not respond to at least one antidepressant. It may help by changing brain signaling linked to depression symptoms.
This Phase 2 trial tests whether an NMDA-targeted treatment can improve symptoms of major depressive disorder (MDD). You may be able to join if your depression diagnosis and symptom score fit, and you meet several safety and study-following requirements.
This Phase 2 trial tests a single medicine intended to help people with schizophrenia who cannot take standard antipsychotic medications due to side effects or poor response. It may help reduce schizophrenia symptoms, but whether you can join depends on your diagnosis, medication history, and health conditions.
Hear when a new Bipolar I Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.